Cibus (CBUS) EBITDA Margin (2016 - 2026)
Cibus (CBUS) posted EBITDA Margin of 2135.67% for Q4 2025, up 14.92% sequentially from 2510.24% in Q3 2025, and down 64854.0% YoY from N/an in Q4 2024.
Cibus (CBUS) EBITDA Margin (2016 - 2026) Analysis & Trends
Cibus has reported EBITDA Margin for 10 years, with the latest figure at 2135.67% in Q4 2025.
- Quarterly EBITDA Margin fell 64854.0% year-over-year to 2135.67% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 2680.1% (up 338268.0% YoY) and the FY2025 annual result came in at 2680.1%, up 338268.0% from the prior year.
- EBITDA Margin grew to 2135.67% in Q4 2025 per CBUS's latest filing, from 2510.24% in the prior quarter.
- Over five years, EBITDA Margin peaked at 50.37% in Q2 2021 and troughed at 24416.32% in Q4 2023.
- A 5-year average of 6960.83% and a median of 3703.14% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2024: EBITDA Margin slumped 1880820 bps in 2022, then soared 2292919 bps in 2024.
- Over 5 years, EBITDA Margin stood at 345.34% in 2021, then slumped by 2184 bps to 7888.1% in 2022, then plunged by 210 bps to 24416.32% in 2023, then jumped by 94 bps to 1487.13% in 2024, then sank by 44 bps to 2135.67% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 2135.67%, 2510.24%, and 1923.47% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Cibus | 131.25 Mn | 110.82 Mn | - | -1,300.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,300.30% |
| Dec 31, 2025 | -2,135.67% |
| Sep 30, 2025 | -2,510.24% |
| Jun 30, 2025 | -1,923.47% |
| Mar 31, 2025 | -4,020.41% |
| Dec 31, 2024 | -1,487.13% |
| Sep 30, 2024 | -12,023.82% |
| Jun 30, 2024 | -2,563.48% |
| Mar 31, 2024 | -3,385.87% |
| Dec 31, 2023 | -24,416.32% |
| Sep 30, 2023 | -5,430.95% |
| Jun 30, 2023 | -9,802.54% |
| Mar 31, 2023 | -10,626.19% |
| Dec 31, 2022 | -7,888.10% |
| Sep 30, 2022 | -14,769.05% |
| Jun 30, 2022 | -16,500.00% |
| Mar 31, 2022 | -19,028.13% |
| Dec 31, 2021 | -345.34% |
| Sep 30, 2021 | -89.63% |
| Jun 30, 2021 | -50.37% |